Pramana Pharmaceuticals Inc., is focused on cardiometabolic disease. Pramana has discovered and developed a novel small molecule platform that powers a new mechanism of action to treat metabolic dysregulation. The company's development program is led by a world class big pharma multi functional scientific team with a strong track record of drug success.

Pramana has been granted broad genus patents including Composition of Matter to treat Diabetes, Obesity, NASH, and Neurodenergative disorders with this novel multi modal mechanism. Recent preclinical data has led to additional patent filings for combination therapy.

Pramana is advancing certain compounds through INDe studies for various indications. The breakthrough preclinical data has enabled opportunities for an accelerated First in Human clinical path. Phillip Crooker, Ex Staff Counsel for the FDA in New Drug Research and Evaluation has recently joined the Pramana team.